Neuroprotective therapies for Alzheimer's disease

Current Pharmaceutical Design

Volumn 12, Issue 6, 2006, Pages 705-717

  Huber, Anke ^a   Stuchbury, Grant ^a   Bürkle, Alexander ^b   Burnell, Jim ^a   Münch, Gerald ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Alzheimer's disease; Antioxidants; Neuroprotection; NMDA receptor antagonists; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; ANTHOCYANOSIDE DERIVATIVE; ANTIOXIDANT; ASCORBIC ACID; BETA SECRETASE; CHOLINESTERASE INHIBITOR; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLAVONOL; GAMMA SECRETASE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; SUPEROXIDE; SUPEROXIDE DISMUTASE; TAU PROTEIN; THIOCTIC ACID; UNINDEXED DRUG; NEUROPROTECTIVE AGENT;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL CULTURE; CELL DAMAGE; DISEASE COURSE; DISEASE MODEL; DRUG STRUCTURE; GLIA CELL; HUMAN; INFLAMMATION; MITOCHONDRION; MITOSIS; NERVE CELL; NERVE CELL LESION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY BURST; REVIEW; SENILE PLAQUE; VITAMIN SUPPLEMENTATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS;

EID: 33645276052     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474251     Document Type: Review

References (122)

1. Hernandez R. Demography of ageing. Bold 1992; 2: 8-12.
2. Yesavage JA, O'Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, et al. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res 2002; 36: 281-6.
3. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002; 23: 213-31.
4. Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003; 138: 400-10.
5. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8; discussion 278-84.
6. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
7. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002; 1: 1-31.
8. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 2003; 180: 144-55.
9. Butterfield DA, Grifin S, Münch G, Pasinetti GM. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis 2002; 4: 193-201.
10. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003; 85: 1394-401.
11. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, et al. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 2003; 16: 77-81.
12. Münch G, Schicktanz D, Behme A, Gerlach M, Riederer P, Palm D, et al. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol 1999; 17: 1006-10.
13. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing Dev 2001; 122: 735-55.
14. Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, et al. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 2001; 920: 32-40.
15. Münch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev 1997; 23: 134-43.
16. Dickson DW, Sinicropi S, Yen SH, Ko LW, Mattiace LA, Bucala R, et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 1996; 17: 733-43.
17. Dukic-Stefanovic S, Gasic-Milenkovic J, Deuther-Conrad W, Münch G. Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J Neurochem 2003; 87: 2609-2615.
18. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000; 27: 1-8.
19. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54: 276-81.
20. Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F. beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils, A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem 1999; 274: 15493-9.
21. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 2005; 386: 401-16.
22. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007-17.
23. Thomas EL. Myeloperoxidase, hydrogen peroxide, chloride antimicrobial system: nitrogen-chlorine derivatives of bacterial components in bactericidal action against Escherichia coli. Infect Immun 1979; 23: 522-31.
24. Raichle ME, Gusnard DA. Appraising the brain's energy budget. Proc Natl Acad Sci USA 2002; 99: 10237-9.
25. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999; 9: 133-46.
26. Fridovich I. Superoxide dismutases. An adaptation to a paramagnetic gas. J Biol Chem 1989; 264: 7761-4.
27. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-95.
28. Rego AC, Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 2003; 28: 1563-74.
29. Dumuis A, Sebben M, Haynes L, Pin JP, Bockaert J. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 1988; 336: 68-70.
30. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1986; 55: 69-102.
31. Patel M, Day BJ, Crapo JD, Fridovich I, McNamara JO. Requirement for superoxide in excitotoxic cell death. Neuron 1996; 16: 345-55.
32. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29: 222-30.
33. Cheeseman KH, Slater TF. An introduction to free radical biochemistry. Br Med Bull 1993; 49: 481-93.
34. Mutze S, Hebling U, Stremmel W, Wang J, Arnhold J, Pantopoulos K, et al. Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1. J Biol Chem 2003; 278: 40542-9.
35. Brioukhanov AL, Netrusov AI. Catalase and superoxide dismutase: distribution, properties, and physiological role in cells of strict anaerobes. Biochemistry (Mosc) 2004; 69: 949-62.
36. Edenharder R, Grunhage D. Free radical scavenging abilities of flavonoids as mechanism of protection against mutagenicity induced by tert-butyl hydroperoxide or cumene hydroperoxide in Salmonella typhimurium TA102. Mutat Res 2003; 540: 1-18.
37. Leeuwenburgh C, Hansen P, Shaish A, Holloszy JO, Heinecke JW. Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. Am J Physiol 1998; 274: R453-61.
38. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.
39. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-47.
40. Liu X, Theil EC. Ferritins: dynamic management of biological iron and oxygen chemistry. Acc Chem Res 2005; 38: 167-75.
41. Yamagishi S, Inagaki Y, Takeuchi M, Sasaki N. Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease? Med Hypotheses 2004; 63: 115-7.
42. Takumida M, Anniko M, Popa R, Zhang DM. Lipopolysaccharide-induced expression of inducible nitric oxide synthase in the guinea pig organ of Corti. Hear Res 2000; 140: 91-8.
43. Brown GC. Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1999; 1411: 351-69.
44. Kissner R, Nauser T, Kurz C, Koppenol WH. Peroxynitrous acid - where is the hydroxyl radical? IUBMB Life 2003; 55: 567-72.
45. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992; 42: 733-8.
46. Nicoletti F, Magri G, Ingrao F, Bruno V, Catania MV, Dell'Albani P, et al. Excitatory amino acids stimulate inositol phospholipid hydrolysis and reduce proliferation in cultured astrocytes. J Neurochem 1990; 54: 771-7.
47. Greenamyre JT, Porter RH. Anatomy and physiology of glutamate in the CNS. Neurology 1994; 44: S7-13.
48. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205-12.
49. Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH, Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann Transplant 2004; 9: 81-3.
50. Rose RC. Transport of ascorbic acid and other water-soluble vitamins. Biochim Biophys Acta 1988; 947: 335-66.
51. Winkler BS. In vitro oxidation of ascorbic acid and its prevention by GSH. Biochim Biophys Acta 1987; 925: 258-64.
52. Sies H. Relationship between free radicals and vitamins: an overview. Int J Vitam Nutr Res Suppl 1989: 30: 215-23.
53. Ciani E, Groneng L, Voltattorni M, Rolseth V, Contestabile A, Paulsen RE. Inhibition of free radical production or free radical scavenging protects from the excitotoxic cell death mediated by glutamate in cultures of cerebellar granule neurons. Brain Res 1996; 728: 1-6.
54. Medina S, Martinez M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res 2002; 36: 1179-84.
55. Lockhart BP, Benicourt C, Junien JL, Privat A. Inhibitors of free radical formation fail to attenuate direct beta-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res 1994; 39: 494-505.
56. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287: 3223-9.
57. Tappel AL. Vitamin E, free radical peroxidation of lipids. Ann N Y Acad Sci 1972; 203: 12-28.
58. Niki E. Interaction of ascorbate and alpha-tocopherol. Ann N Y Acad Sci 1987; 498: 186-99.
59. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001; 66: 163-70.
60. Yatin SM, Varadarajan S, Butterfield DA. Vitamin E Prevents Alzheimer's Amyloid beta-Peptide (1-42)-Induced Neuronal Protein Oxidation and Reactive Oxygen Species Production. J Alzheimers Dis 2000; 2: 123-131.
61. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287: 3230-7.
62. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61: 82-8.
63. Packer L, Witt EH, Tritschler HJ, alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Mod 1995; 19: 227-50.
64. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004; 11: 1135-46.
65. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 2004; 43: 560-8.
66. Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, et al. Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett 2001; 312: 125-8.
67. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis 2003; 5: 229-39.
68. Hager K, Marahrens A, Kenklies M, Riederer P, Münch G. Alphalipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 2001; 32: 275-282.
69. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 43: 89-143.
70. Rice-Evans C. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Proc Soc Exp Biol Med 1999; 220: 262-6.
71. Haenen GR, Bast A. Nitric oxide radical scavenging of flavonoids. Methods Enzymol 1999; 301: 490-503.
72. Pannala AS, Rice-Evans CA, Halliwell B, Singh S. Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenols. Biochem Biophys Res Commun 1997; 232: 164-8.
73. Nanjo F, Mori M, Goto K, Hara Y. Radical scavenging activity of tea catechins and their related compounds. Biosci Biotechnol Biochem 1999; 63: 1621-3.
74. Bors W, Michel C, Stettmaier K. Electron paramagnetic resonance studies of radical species of proanthocyanidins and gallate esters. Arch Biochem Biophys 2000; 374: 347-55.
75. Bors W, Michel C. Antioxidant capacity of flavanols and gallate esters: pulse radiolysis studies. Free Radic Biol Med 1999; 27: 1413-26.
76. Skrzydlewska E, Ostrowska J, Farbiszewski R, Michalak K. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine 2002; 9: 232-8.
77. Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol 1991; 42: 1673-81.
78. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res 1992; 52: 4050-2.
79. Agarwal R, Katiyar SK, Khan SG, Mukhtar H. Protection against ultraviolet B radiation-induced effects in the skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea. Photochem Photobiol 1993; 58: 695-700.
80. Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 2003; 17: 952-4.
81. Lin YL, Tsai SH, Lin-Shiau SY, Ho CT, Lin JK. Theaflavin-3, 3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur J Pharmacol 1999; 367: 379-88.
82. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998; 18: 8126-32.
83. Forster DP, Newens AJ, Kay DW, Edwardson JA. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J Epidemiol Community Health 1995; 49: 253-8.
84. Chan DK, Woo J, Ho SC, Pang CP, Law LK, Ng PW, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998; 65: 781-4.
85. Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 2003; 216: 163-7.
86. Bilia AR. Ginkgo biloba L. Fitoterapia 2002; 73: 276-9.
87. Ahlemeyer B, Selke D, Schaper C, Klumpp S, Krieglstein J. Ginkgolic acids induce neuronal death and activate protein phosphatase type-2C. Eur J Pharmacol 2001; 430: 1-7.
88. De Ruvo, C, Amodio R, Algeri S, Martelli N, Intilangelo A, D'Ancona GM, et al. Nutritional antioxidants as antidegenerative agents. Int J Dev Neurosci 2000; 18: 359-66.
89. Dajas F, Rivera-Megret F, Blasina F, Arredondo F, Abin-Carriquiry JA, Costa G, et al. Neuroprotection by flavonoids. Braz J Med Biol Res 2003; 36: 1613-20.
90. Bedir E, Tatli, II, Khan RA, Zhao J, Takamatsu S, Walker LA, et al. Biologically active secondary metabolites from Ginkgo biloba. J Agric Food Chem 2002; 50: 3150-5.
91. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999; 4: 144-61.
92. Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res 2001; 15: 449-51.
93. Colak O, Sahin A, Alatas O, Inal M, Yasar B, Kiper H. The effect of Ginkgo biloba on the activity of catalase and lipid peroxidation in experimental strangulation ileus. Int J Clin Lab Res 1998; 28: 69-71.
94. Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gardes-Albert M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol 1994; 234: 462-75.
95. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo, biloba extracts. Neurobiol Dis 2004; 16: 454-60.
96. Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis 2003; 5: 287-300.
97. Roth A, Schaffner W, Hertel C. Phytoestrogen kaempferol (3, 4′, 5, 7-tetrahydroxyflavone) protects PC12 and T47D cells from beta-amyloid-induced toxicity. J Neurosci Res 1999; 57: 399-404.
98. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996; 29: 47-56.
99. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, et al. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003; 58: 372-7.
100. Cho J, Kang JS, Long PH, Jing J, Back Y, Chung KS. Antioxidant and memory enhancing effects of purple sweet potato anthocyanin and cordyceps mushroom extract. Arch Pharm Res 2003; 26: 821-5.
101. Galli RL, Shukitt-Hale B, Youdim KA, Joseph JA. Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits. Ann N Y Acad Sci 2002; 959: 128-32.
102. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-4.
103. Schouten A, Wagemakers L, Stefanato FL, van der Kaaij RM, van Kan JA. Resveratrol acts as a natural profungicide and induces self-intoxication by a specific laccase. Mol Microbiol 2002; 43: 883-94.
104. Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663-73.
105. Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003; 49: 380-3.
106. Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, et al. Lipoproteins in the central nervous system. Ann N Y Acad Sci 2000; 903: 167-75.
107. Sun WG, Liao HL, Huang ZS. Intervention effect of Chinese herbal medicine on changes of immune system in senile dementia. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001; 21: 716-8.
108. Chanvitayapongs S, Draczynska-Lusiak B, Sun AY. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 1997; 8: 1499-502.
109. Ferrieres J. The French paradox: lessons for other countries. Heart 2004; 90: 107-11.
110. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153: 185-92.
111. Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc 2004; 52: 540-6.
112. Kato T. Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801. Nippon Yakurigaku Zasshi 2004; 124: 145-51.
113. Medvedev IO, Malyshkin AA, Belozertseva IV, Sukhotina IA, Sevostianova NY, Aliev K, et al. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology 2004; 47: 175-83.
114. Stone TW. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Investig Drugs 2001; 10: 633-45.
115. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002; 958: 210-21.
116. Kucheryanu VG, Kryzhanovskii GN. Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp Biol Med 2000; 130: 629-32.
117. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2003; CD003154.
118. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
119. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46.
120. Casetta I, Govoni V, Granieri E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Design 2005; 11(16): 2033-52.
121. Koch HJ, Szecsey A, Haen E. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Curr Pharm Design 2004; 10(3): 253-9.
122. Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Design 2004; 10(25): 3177-84.